Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioMimetic Therapeutics
Franklin, Tennessee, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company developed protein-based regenerative therapies with a focus on musculoskeletal healing. Its lead product Augment Bone Graft received regulatory approvals outside the US and was under FDA review at time of acquisition. Clinical programs included injectable formulations for tendon injuries with promising preclinical data advancing to Phase II trials as of early 2013.[5][6]
- Therapeutic areas
- OtherNeurologyRheumatology
- Modalities
- Protein therapeutics (recombinant human platelet-derived growth factor BB - rhPDGF-BB)[1][2][6]
- Industry
- Biotech
02
Partnerships
No major pharma partnerships disclosed; investors include Novo Holdings, Burrill & Company among others [1].
Beyond the preview
Go deeper on BioMimetic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMimetic Therapeutics.